Mark Schoenberg Sells 5,162 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) Stock

UroGen Pharma Ltd. (NASDAQ:URGN) insider Mark Schoenberg sold 5,162 shares of UroGen Pharma stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $7.37, for a total value of $38,043.94. Following the sale, the insider now directly owns 153,378 shares of the company’s stock, valued at approximately $1,130,395.86. This represents a 3.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

UroGen Pharma Stock Performance

Shares of URGN stock opened at $11.08 on Friday. The stock has a market cap of $510.87 million, a PE ratio of -3.52 and a beta of 0.40. The business has a 50-day simple moving average of $8.49 and a 200-day simple moving average of $10.07. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. UroGen Pharma Ltd. has a 52-week low of $3.42 and a 52-week high of $20.70.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The firm had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. On average, equities analysts expect that UroGen Pharma Ltd. will post -3.12 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on URGN shares. Oppenheimer lowered their price target on UroGen Pharma from $36.00 to $10.00 and set an “outperform” rating for the company in a research report on Tuesday, June 3rd. The Goldman Sachs Group lowered their price target on UroGen Pharma from $16.00 to $3.00 and set a “neutral” rating for the company in a research report on Thursday, May 22nd. HC Wainwright cut UroGen Pharma from a “buy” rating to a “neutral” rating in a research report on Thursday, May 22nd. LADENBURG THALM/SH SH started coverage on UroGen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price target for the company. Finally, Scotiabank started coverage on UroGen Pharma in a research report on Wednesday, April 16th. They set a “sector outperform” rating and a $23.00 price target for the company. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.14.

Hedge Funds Weigh In On UroGen Pharma

A number of large investors have recently bought and sold shares of URGN. Rhumbline Advisers raised its holdings in UroGen Pharma by 2.8% in the 4th quarter. Rhumbline Advisers now owns 51,270 shares of the company’s stock worth $546,000 after purchasing an additional 1,402 shares during the period. Bank of New York Mellon Corp raised its holdings in UroGen Pharma by 7.3% in the 4th quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company’s stock worth $1,001,000 after purchasing an additional 6,430 shares during the period. ARK Investment Management LLC raised its holdings in UroGen Pharma by 15.2% in the 4th quarter. ARK Investment Management LLC now owns 140,148 shares of the company’s stock worth $1,493,000 after purchasing an additional 18,514 shares during the period. Oppenheimer & Co. Inc. acquired a new position in UroGen Pharma in the 4th quarter worth about $126,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in UroGen Pharma by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company’s stock worth $996,000 after purchasing an additional 3,024 shares during the period. Institutional investors and hedge funds own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.